The application of physiologically-based pharmacokinetic (PBPK) modeling is coming of
age in drug development and regulation, reflecting significant advances over the past 10 …

Fentanyl was structurally designed by Paul Janssen in the early 1960s as a potent opioid
analgesic (100-fold more potent than morphine). It is a full agonist at μ-opioid receptors and …

Background The authors hypothesized a difference in plasma-effect site equilibration,
depicted by a first-order constant k (e0), depending on the injection rate of propofol. Methods …

The purpose of this article is to systematically review the use of fentanyl as an analgesic for
breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a …

Initial feasibility of a novel closed-loop controller created by our group for closed-loop control
of vasopressor infusions has been previously described. In clinical practice, vasopressor …

Analgesia from most opioids is mediated by μ receptors located mainly in the central
nervous system. Previous studies have shown a different pharmacological profile of …

Three advanced models of pharmacokinetics are described. In the first class are
physiologically based pharmacokinetic models based on in vitro data on transport and …

SUMMARY 1 Drugs that target the central nervous system (CNS) are under‐represented in
the pharmacopoeia because of the difficulties of overcoming passive and active defences of …

Background. The predominant effect of opioids on respiratory pattern during anaesthesia is
an increase in the duration of expiration (an effect on 'timing'), but there may also be …

Oxycodone is an opioid analgesic that is administered orally or parenterally. The time-
course of opioid action is a function of the systemic kinetics of the opioid, and the rate and …